Mobile Menu

FoG 2020 Presentation Ben Davies, University of Oxford: Crispr/Cas9 site-specific nucleases for the production of genetically modified disease models

Dr. Ben Davies received his PhD in molecular biology from the University of Edinburgh where he first encountered gene targeting techniques at the Centre for Genome Research. After a postdoc at the Charite Hospital Berlin, he moved into commercial biotech working as scientific director for a start-up transgenic service company based at the University Hospital Hamburg-Eppendorf which was then merged with the French Biotech company, Genoway. After 4 years in this role, he moved to Oxford where he runs the transgenic core research group at the Wellcome Centre for Human Genetics at the University of Oxford, a position he has held for the last 12 years.

Ben Davies, University of Oxford